Replies to post #83653 on Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

I care more about the PSA data,and possible Cervix data,because those will make or break the big deals I expect. The NEO phase 1 data will be what`s expected, Safe. and then it`ll come down to the big Phase 2,efficacy. Adxs`s share price does`nt even reflect the NEO at all,so it`s possible that even a go ahead on safety will be enough to start getting some market cap back. Adxs`s market cap is 15 million lower then cash on hand and not one penny for any of the companies science. It`s ridiculous and NEO data could help to start correcting that at least. I`m hoping for a deal with Merck,and it could be huge. It could wind up that Merck wants the Axal/PSA and the HOT for it,and the HOT/NSCLC,because that could also work for them. Maybe they take all of HOT,and the Axal/PSA,and we then are fully funded going forward,,who knows. Fingers crossed for a shareholder break,for goodness sake.

[mm2k]

Hovacre, could you please summarize the results?

[ubmmg]

ours will likely not be much more explosive than this

I'm guessing that the funds/analysts are fully aware of the current status of our NEO trial as it's an open label CT. There likely have not been earth-shattering miracle cures with the NEO dosing, and this is reflected in the share price and the direction of Advaxis. It's really shortsighted to assume that nobody on the Street knows nothing about our/Amgen trial, and everyone is in the dark with respect to the safety and efficacy. Likely, we will have to wait for Ph2 data to see anything paradigm shifting results. And that's a looong way to go.